BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 27683111)

  • 1. miR-135a promotes gastric cancer progression and resistance to oxaliplatin.
    Yan LH; Chen ZN; Li-Li ; Chen J; Wei WE; Mo XW; Qin YZ; Lin Y; Chen JS
    Oncotarget; 2016 Oct; 7(43):70699-70714. PubMed ID: 27683111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells.
    Zheng H; Wang JJ; Yang XR; Yu YL
    World J Gastroenterol; 2020 Feb; 26(5):499-513. PubMed ID: 32089626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-493 mediated DKK1 down-regulation confers proliferation, invasion and chemo-resistance in gastric cancer cells.
    Jia X; Li N; Peng C; Deng Y; Wang J; Deng M; Lu M; Yin J; Zheng G; Liu H; He Z
    Oncotarget; 2016 Feb; 7(6):7044-54. PubMed ID: 26799283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA NNT-AS1 sponges miR-424/E2F1 to promote the tumorigenesis and cell cycle progression of gastric cancer.
    Chen B; Zhao Q; Guan L; Lv H; Bie L; Huang J; Chen XB
    J Cell Mol Med; 2018 Oct; 22(10):4751-4759. PubMed ID: 30006956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reciprocal regulation loop of Notch2 pathway and miR-23b in controlling gastric carcinogenesis.
    Huang TT; Ping YH; Wang AM; Ke CC; Fang WL; Huang KH; Lee HC; Chi CW; Yeh TS
    Oncotarget; 2015 Jul; 6(20):18012-26. PubMed ID: 26041881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-218 suppresses gastric cancer cell cycle progression through the CDK6/Cyclin D1/E2F1 axis in a feedback loop.
    Deng M; Zeng C; Lu X; He X; Zhang R; Qiu Q; Zheng G; Jia X; Liu H; He Z
    Cancer Lett; 2017 Sep; 403():175-185. PubMed ID: 28634044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
    Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
    Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361.
    Wu X; Zheng Y; Han B; Dong X
    Biomed Pharmacother; 2018 Mar; 99():832-838. PubMed ID: 29710482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor expression of microRNA-135b results in the inhibition of cisplatin resistance and proliferation and induces the apoptosis of gastric cancer cells through MST1-mediated MAPK signaling pathway.
    Zhou J; Chen Q
    FASEB J; 2019 Mar; 33(3):3420-3436. PubMed ID: 30576232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R.
    Gong Y; Ren J; Liu K; Tang LM
    World J Gastroenterol; 2015 Mar; 21(10):2949-58. PubMed ID: 25780292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-25 promotes gastric cancer proliferation, invasion, and migration by directly targeting F-box and WD-40 Domain Protein 7, FBXW7.
    Gong J; Cui Z; Li L; Ma Q; Wang Q; Gao Y; Sun H
    Tumour Biol; 2015 Sep; 36(10):7831-40. PubMed ID: 25944166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.
    Zhang J; Liu L; Sun Y; Xiang J; Zhou D; Wang L; Xu H; Yang X; Du N; Zhang M; Yan Q; Xi X
    Oncotarget; 2016 May; 7(18):26516-34. PubMed ID: 27049921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-646 inhibited cell proliferation and EMT-induced metastasis by targeting FOXK1 in gastric cancer.
    Zhang P; Tang WM; Zhang H; Li YQ; Peng Y; Wang J; Liu GN; Huang XT; Zhao JJ; Li G; Li AM; Bai Y; Chen Y; Ren YX; Li GX; Wang YD; Liu SD; Wang JD
    Br J Cancer; 2017 Aug; 117(4):525-534. PubMed ID: 28632723
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Shao Q; Xu J; Guan X; Zhou B; Wei W; Deng R; Li D; Xu X; Zhu H
    Int J Med Sci; 2018; 15(1):86-94. PubMed ID: 29333091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATXN2L upregulated by epidermal growth factor promotes gastric cancer cell invasiveness and oxaliplatin resistance.
    Lin L; Li X; Pan C; Lin W; Shao R; Liu Y; Zhang J; Luo Y; Qian K; Shi M; Bin J; Liao Y; Liao W
    Cell Death Dis; 2019 Feb; 10(3):173. PubMed ID: 30787271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-215 promotes malignant progression of gastric cancer by targeting RUNX1.
    Li N; Zhang QY; Zou JL; Li ZW; Tian TT; Dong B; Liu XJ; Ge S; Zhu Y; Gao J; Shen L
    Oncotarget; 2016 Jan; 7(4):4817-28. PubMed ID: 26716895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E2F1-activated SPIN1 promotes tumor growth via a MDM2-p21-E2F1 feedback loop in gastric cancer.
    Lv BB; Ma RR; Chen X; Zhang GH; Song L; Wang SX; Wang YW; Liu HT; Gao P
    Mol Oncol; 2020 Oct; 14(10):2629-2645. PubMed ID: 32767629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of PAX3-MET pathways due to miR-206 loss promotes gastric cancer metastasis.
    Zhang L; Xia L; Zhao L; Chen Z; Shang X; Xin J; Liu M; Guo X; Wu K; Pan Y; Fan D
    Carcinogenesis; 2015 Mar; 36(3):390-9. PubMed ID: 25653235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cullin 4A (CUL4A), a direct target of miR-9 and miR-137, promotes gastric cancer proliferation and invasion by regulating the Hippo signaling pathway.
    Deng J; Lei W; Xiang X; Zhang L; Lei J; Gong Y; Song M; Wang Y; Fang Z; Yu F; Feng M; Sun Z; Chen J; Zhan Z; Xiong J
    Oncotarget; 2016 Mar; 7(9):10037-50. PubMed ID: 26840256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of E2F1 in human gastric carcinoma is involved in anti-cancer drug resistance.
    Yan LH; Wei WY; Cao WL; Zhang XS; Xie YB; Xiao Q
    BMC Cancer; 2014 Dec; 14():904. PubMed ID: 25466554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.